TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:00
BICYCLE THERAPEUTICS plc ( BCYC ) https://www.bicycletherapeutics.com
24.53USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
BCYC
9.51%
SPY
32.74%
-7.19%
BCYC
SPY
92.93%
BCYC
0.00%
SPY
224.41%
BCYC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1081.59
585.86
0.48
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.70
43.56
2.92
-2.23
0.00
-3.26
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-949.12
100.00
-666.47
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-47.27
-46.02
0.00
Other Earnings and Cash Flow Stats:
BICYCLE THERAPEUTICS plc ( BCYC ) Net Income TTM ($MM) is -147.29
BICYCLE THERAPEUTICS plc ( BCYC ) Operating Income TTM ($MM) is -154.57
BICYCLE THERAPEUTICS plc ( BCYC ) Owners' Earnings Annual ($MM) is -46.97
BICYCLE THERAPEUTICS plc ( BCYC ) Current Price to Owners' Earnings ratio is -16.33
BICYCLE THERAPEUTICS plc ( BCYC ) EBITDA TTM ($MM) is -146.71
BICYCLE THERAPEUTICS plc ( BCYC ) EBITDA Margin is -666.47%
Capital Allocation:
BICYCLE THERAPEUTICS plc ( BCYC ) has paid 0.00 dividends per share and bought back -12.771107 million shares in the past 12 months
BICYCLE THERAPEUTICS plc ( BCYC ) has reduced its debt by 16.752 million USD in the last 12 months
Capital Structure:
BICYCLE THERAPEUTICS plc ( BCYC ) Interest-bearing Debt ($MM) as of last quarter is 30
BICYCLE THERAPEUTICS plc ( BCYC ) Annual Working Capital Investments ($MM) are 27
BICYCLE THERAPEUTICS plc ( BCYC ) Book Value ($MM) as of last quarter is 370
BICYCLE THERAPEUTICS plc ( BCYC ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
BICYCLE THERAPEUTICS plc ( BCYC ) has 526 million in cash on hand as of last quarter
BICYCLE THERAPEUTICS plc ( BCYC ) has 69 million of liabilities due within 12 months, and long term debt 30 as of last quarter
BICYCLE THERAPEUTICS plc ( BCYC ) has 42 common shares outstanding as of last quarter
BICYCLE THERAPEUTICS plc ( BCYC ) has 0 million USD of preferred stock value
Academic Scores:
BICYCLE THERAPEUTICS plc ( BCYC ) Altman Z-Score is 1.69 as of last quarter
BICYCLE THERAPEUTICS plc ( BCYC ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
BICYCLE THERAPEUTICS plc ( BCYC ) largest shareholder is HHG PLC owning 910930 shares at 22.35 ($MM) value
Travis Alvin Thompson(an insider) Sold 604 shares of BICYCLE THERAPEUTICS plc ( BCYC ) for the amount of $10570.00 on 2024-01-03
8.55% of BICYCLE THERAPEUTICS plc ( BCYC ) is held by insiders, and 82.16% is held by institutions
BICYCLE THERAPEUTICS plc ( BCYC ) went public on 2019-05-23
Other BICYCLE THERAPEUTICS plc ( BCYC ) financial metrics:
FCF:-90.65
Unlevered Free Cash Flow:-182.26
EPS:-4.70
Operating Margin:-949.12
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-53.81
Beta:0.00
Buffet's Owners Earnings:-46.97
Price to Owner's Earnings:-16.33
About BICYCLE THERAPEUTICS plc ( BCYC ) :
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.